

COMORBIDITY OF GUILLAIN-BARRE SYNDROME AND COVID-19 INFECTION: A CASE REPORT AND A REVIEW OF THE CURRENT LITERATURE

Radomir Damjanović^{1,2}, Aleksandar Stojanov^{1,2}, Ninoslava Simić^{1,3}, Andrija Jović^{1,4},
Dejan Popović^{1,5}

1University Clinical Center Niš, COVID hospital, Niš

2University Clinical Center Niš, Neurology Clinic, Niš,

3 University Clinical Center Niš, Mental Health Protection Center,
Department for Child and Adolescent Psychiatry Niš, Serbia

4 University Clinical Center Niš, Dermatovenerology Clinic, Niš, Serbia

5 University Clinical Center Niš, Cardiovascular Diseases Clinic, Niš, Srbija

Contact: Radomir Damjanović

48 Dr. Zoran Djindjića Blvd., 18000 Niš, Serbia

Tel: +381 61 44 86424

E-mail: rdamjanovic@gmail.com

Guillain-Barre syndrome is an immunologically mediated polyradiculoneuropathy characterized by a monophasic course, with a clinical peak within 4 weeks of disease onset. There have been several reports of Guillain-Barré syndrome, related to COVID-19, days or weeks after the onset of respiratory symptoms. In contrast to that, we describe a case of acute sensorimotor demyelinating polyradiculoneuropathy, followed by COVID-19 infection. Our patient was successfully treated with intravenous immunoglobulins while COVID-19 was treated according to the latest clinical management protocol. In our case, neuropathy symptoms showed a parainfectious profile rather than a post-infectious one, which is uncommon in Guillain-Barré syndrome. *Acta Medica Medianae* 2023;62(1):50-55.

Key words: Guillain-Barré syndrome (GBS), Coronavirus disease 2019 (COVID-19), weakness